Gary Feiss

712 total citations
33 papers, 540 citations indexed

About

Gary Feiss is a scholar working on Immunology and Allergy, Dermatology and Epidemiology. According to data from OpenAlex, Gary Feiss has authored 33 papers receiving a total of 540 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology and Allergy, 10 papers in Dermatology and 9 papers in Epidemiology. Recurrent topics in Gary Feiss's work include Allergic Rhinitis and Sensitization (11 papers), Asthma and respiratory diseases (9 papers) and Dermatology and Skin Diseases (8 papers). Gary Feiss is often cited by papers focused on Allergic Rhinitis and Sensitization (11 papers), Asthma and respiratory diseases (9 papers) and Dermatology and Skin Diseases (8 papers). Gary Feiss collaborates with scholars based in Netherlands, United States and United Kingdom. Gary Feiss's co-authors include Jacobus Burggraaf, Robert Rißmann, Joseph A. Smith, Tessa Niemeyer‐van der Kolk, Martijn B. A. van Doorn, Brandon Simpson, Errol P. Prens, Matthijs Moerland, Robert J. Dockhorn and Marieke L. de Kam and has published in prestigious journals such as International Journal of Molecular Sciences, CHEST Journal and Journal of Allergy and Clinical Immunology.

In The Last Decade

Gary Feiss

32 papers receiving 506 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary Feiss Netherlands	14	163	161	131	125	87	33	540
Jann Lübbe Switzerland	17	155 1.0×	377 2.3×	181 1.4×	650 5.2×	67 0.8×	32	1.1k
José María Peña Spain	9	31 0.2×	89 0.6×	194 1.5×	43 0.3×	16 0.2×	13	504
Susanne Loeliger Switzerland	7	162 1.0×	124 0.8×	74 0.6×	80 0.6×	40 0.5×	10	724
Yousri M. Hussein Egypt	14	127 0.8×	82 0.5×	66 0.5×	88 0.7×	28 0.3×	34	482
A.L.A. Kuijpers Netherlands	16	76 0.5×	18 0.1×	80 0.6×	241 1.9×	41 0.5×	23	710
Samar Ojaimi Australia	13	34 0.2×	35 0.2×	212 1.6×	35 0.3×	40 0.5×	35	640
Helena Kahu Sweden	16	63 0.4×	78 0.5×	35 0.3×	25 0.2×	83 1.0×	19	776
Carolyn Hawkins Australia	9	52 0.3×	53 0.3×	69 0.5×	19 0.2×	40 0.5×	20	326
Paul Enarson Canada	14	39 0.2×	115 0.7×	156 1.2×	33 0.3×	52 0.6×	23	843
Talveer S. Mandur Canada	9	111 0.7×	116 0.7×	69 0.5×	27 0.2×	41 0.5×	9	558

Countries citing papers authored by Gary Feiss

Since Specialization

Citations

This map shows the geographic impact of Gary Feiss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Feiss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Feiss more than expected).

Fields of papers citing papers by Gary Feiss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Feiss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Feiss. The network helps show where Gary Feiss may publish in the future.

Co-authorship network of co-authors of Gary Feiss

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Feiss. A scholar is included among the top collaborators of Gary Feiss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Feiss. Gary Feiss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kam, Marieke L. de, Gary Feiss, Errol P. Prens, et al.. (2023). A multimodal, comprehensive characterization of a cutaneous wound model in healthy volunteers. Experimental Dermatology. 32(7). 1028–1041. 4 indexed citations

Theelen, Bart, Marieke L. de Kam, Gary Feiss, et al.. (2023). Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial. International Journal of Molecular Sciences. 24(18). 14315–14315. 5 indexed citations

Theelen, Bart, Rob J. Vreeken, Gary Feiss, et al.. (2023). Lesional skin of seborrheic dermatitis patients is characterized by skin barrier dysfunction and correlating alterations in the stratum corneum ceramide composition. Experimental Dermatology. 33(1). e14952–e14952. 21 indexed citations

Kleinovink, Jan Willem, Matthijs Moerland, Gary Feiss, et al.. (2020). Host genetics and tumor environment determine the functional impact of neutrophils in mouse tumor models. Journal for ImmunoTherapy of Cancer. 8(2). e000877–e000877. 9 indexed citations

Kolk, Tessa Niemeyer‐van der, Marieke L. de Kam, Martin Becker, et al.. (2020). Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial. Journal of the American Academy of Dermatology. 86(4). 854–862. 34 indexed citations

Grievink, Hendrika W., et al.. (2020). Antimicrobial Peptide Omiganan Enhances Interferon Responses to Endosomal Toll‐Like Receptor Ligands in Human Peripheral Blood Mononuclear Cells. Clinical and Translational Science. 13(5). 891–895. 5 indexed citations

Kolk, Tessa Niemeyer‐van der, Erica S. Klaassen, Gary Feiss, et al.. (2020). Omiganan Enhances Imiquimod‐Induced Inflammatory Responses in Skin of Healthy Volunteers. Clinical and Translational Science. 13(3). 573–579. 19 indexed citations

Kolk, Tessa Niemeyer‐van der, Martijn B. A. van Doorn, Jacobus Burggraaf, et al.. (2019). Inter- and Intra-patient Variability Over Time of Lesional Skin Microbiota in Adult Patients with Atopic Dermatitis. Acta Dermato Venereologica. 100(1). 1–2. 5 indexed citations

Grada, Ayman, Martijn B. A. van Doorn, Edward Lain, Katharine Furst, & Gary Feiss. (2019). LB1092 Topical omiganan for severe papulopustular rosacea: A randomized, vehicle-controlled, double-blind, multicenter study. Journal of Investigative Dermatology. 139(9). B13–B13. 3 indexed citations

10.

Kolk, Tessa Niemeyer‐van der, Hans Pinckaers, Jan Nico Bouwes Bavinck, et al.. (2019). Mobile e‐diary application facilitates the monitoring of patient‐reported outcomes and a high treatment adherence for clinical trials in dermatology. Journal of the European Academy of Dermatology and Venereology. 34(3). 633–639. 15 indexed citations

11.

Feiss, Gary, Koen D. Quint, Maurits N.C. de Koning, et al.. (2019). Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus‐induced genital lesions. British Journal of Clinical Pharmacology. 86(11). 2133–2143. 18 indexed citations

12.

Joerger, Markus, Stefanie Kraff, Alwin D. R. Huitema, et al.. (2012). Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring. Clinical Pharmacokinetics. 51(9). 607–617. 46 indexed citations

13.

Kardos, Keith, Eugene R. Schiff, Karam Mounzer, et al.. (2010). Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. Journal of Virological Methods. 172(1-2). 27–31. 87 indexed citations

14.

Koepke, Jerald W., Roger H. Kobayashi, James P. Rosen, et al.. (1997). Long-Term Safety and Efficacy of Triamcinolone Acetonide Aqueous Nasal Spray for the Treatment of Perennial Allergic Rhinitis. Allergy and Asthma Proceedings. 18(1). 33–37. 13 indexed citations

15.

Storms, William W., et al.. (1996). Efficacy of Triamcinolone Acetonide Aerosol Nasal Inhaler in Children with Perennial Allergic Rhinitis. Pediatric Asthma Allergy & Immunology. 10(2). 59–64. 7 indexed citations

16.

Munk, Zev M., et al.. (1996). Efficacy and Safety of Triamcinolone Acetonide Aqueous Nasal Spray in Patients with Seasonal Allergic Rhinitis. Annals of Allergy Asthma & Immunology. 77(4). 277–281. 30 indexed citations

17.

Dockhorn, Robert J., Sherwin A. Gillman, Gil J. Gross, et al.. (1996). A comparison of effects of triamcinolone acetonide aqueous nasal spray, oral prednisone, and placebo on adrenocortical function in male patients with allergic rhinitis. Journal of Allergy and Clinical Immunology. 98(1). 32–38. 29 indexed citations

18.

Schenkel, Eric, Gary N. Gross, Bob Lanier, et al.. (1996). 61 Triamcinolone acetonide aqueous nasal spray does not alter adrenocortical function in children with allergic rhinitis. Journal of Allergy and Clinical Immunology. 97(1). 198–198. 3 indexed citations

19.

Feiss, Gary, Richard J. Morris, Lyndon E. Mansfield, et al.. (1992). A comparative study of the effects of intranasal triamcinolone acetonide aerosol (ITAA) and prednisone on adrenocortical function. Journal of Allergy and Clinical Immunology. 89(6). 1151–1156. 25 indexed citations

20.

Morris, Raymond G., Gary Feiss, Robert J. Dockhorn, et al.. (1991). 317 A comparative study of the effects of intranasal triamcinolone acetonide and prednisone on adrenocortical function. Journal of Allergy and Clinical Immunology. 87(1). 219–219. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact